Anavex Life Sciences (AVXL)
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases.
Something off on this page? Send us feedback.
Develops oral investigational therapies for neurodegenerative and neurodevelopmental diseases, led by blarcamesine. The pipeline remains clinical-stage and pre-revenue, with no marketed therapy.
Built from a former online-photofinishing business, the company pivoted to drug development. It develops oral, investigational therapies for neurodegenerative and neurodevelopmental diseases, with blarcamesine as its central clinical candidate. Programs include Alzheimer’s disease, Parkinson’s disease, and Rett syndrome.
Clinical studies, translational science, and regulatory pathways form its stated approach. A European marketing-authorisation application for blarcamesine in early Alzheimer’s received a negative CHMP opinion, and re-examination was requested.
Pre-revenue since inception, the business has no marketed therapy. It depends on clinical development, regulatory review, future commercialization routes or partnerships, and continued periodic-reporting compliance.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Oct 24, 2025 | Jones Trading | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $118.3M · Total debt $0 · Total assets $120.1M · Shareholders' equity $112.4M
- Revenue
- $0
- Operating income
- −$6.5M
- Net income
- −$3.2M
No dividends on record.
| Institutions | 40.67% | 37.70M shares | |
|---|---|---|---|
| 188 holders · as of Jun 30, 2026 | |||
| Insiders | 1.68% | 1.55M shares | |
| 2 holders · as of Sep 12, 2025 | |||
| Other | 57.65% | 53.45M shares | |
| remainder | |||
92.70M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.69% | 8.06M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.37% | 4.05M | as of Jun 30, 2026 |
Two Sigma Investments, LPInstitution | 3.29% | 3.05M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.60% | 2.41M | as of Jun 30, 2026 |
State Street CorpInstitution | 2.07% | 1.92M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Eli Lilly
FDA-approved early-Alzheimer's anti-amyloid therapy
- Biogen
Co-commercializes FDA-approved LEQEMBI for early Alzheimer's
- Acadia Pharmaceuticals
Markets FDA-approved DAYBUE for Rett syndrome
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anavex Life Sciences | $2.42 | +0.63% | $222.4M | — | — | — | — |
| Eli Lilly | $1,169.22 | +0.37% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Biogen | $224.36 | +2.42% | $32.37B | 38.8 | 16.9 | 3.3 | +3.4% |
| Acadia Pharmaceuticals | $26.69 | +1.13% | $4.52B | 11.9 | 29.8 | 4.0 | +16.4% |
| Median | 38.8 | 28.6 | 4.0 | +16.4% |